Stanford researchers have developed an innovative, non-invasive therapeutic strategy to treat myocardial fibrosis (MF), a key driver of arrhythmia and heart failure in LMNA-related dilated cardiomyopathy (LMNA-DCM).
Stanford researchers have developed a novel gene therapy vector, AAV-capGL to overcome immune barriers that currently limit the efficacy and safety of adeno-associated virus (AAV)-based gene therapies.
Researchers at Stanford have developed a clinically applicable method of bone marrow conditioning for stem cell transplantation or treatment of hematologic malignancies.
Researchers at Stanford have developed a novel strategy to enhance vaccine efficacy using mRNA lipid nanoparticles (LNPs) encoding immunostimulatory cytokines.
Stanford researchers have developed a novel therapeutic approach for neurodegenerative diseases by targeting endoplasmic reticulum (ER) stress in neurons using CHOP inhibitors, with significant potential for development into first-in-class neuroprotective drugs for neurodegene
Stanford scientists in Dr. Michael Lin's lab have established the use of B-cell reducing agents to improve an oncolytic virus (OV) therapy to rewire cancer signaling while limiting the production of antibodies against the virus in mouse studies.
Stanford researchers have created an optimized stuffer sequence derived from the human BMP-10 3'UTR to enhance the packaging efficiency, productivity, and safety of recombinant adeno-associated virus (rAAV) vectors in gene therapy applications.
Heart failure is a complex cardiovascular disease that affects 26 million people worldwide and is characterized by the inability of the heart to pump blood effectively, leading to a decline in its normal functions.
Stanford researchers have patented a system for precise genetic modification of human embryonic stem cells (ECSs) and induced pluripotent stem cells (iPSCs).
Stanford scientists in Lacramioara Bintu's lab have developed a high-throughput system to identify regulatory domains in human RNA-binding proteins, presenting a new set of tools that could greatly enhance control over gene regulation at the RNA level for therapeutic and synth
Stanford scientists have developed a gene integration system that uses human-derived helicases paired with CRISPR technology to enable precise insertion of long DNA sequences at targeted genomic locations.
Scientists in the Carette Lab at Stanford have developed AAV-Titer cell lines that enable (1) improved and standardized in vitro potency assays (2) determination of a functional titer of AAV vectors of different serotypes and containing different promotors.
Researchers at Stanford University have discovered a first-in-class covalent inhibitor that binds to activated Fis1 and prevents mitochondrial fission and dysfunction.